Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.241 USD 0.00(0%)
Last update at 2026-11-18T21:00:00Z
VOLUME
5000
Market Cap
4.65M

Momentum Score

…

StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, metabolic syndrome, neuropathy, and kidney functions in the United States. It develops and manufactures the eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and the eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of the shoulder, waist, back, neck, upper and lower extremities (arms and legs). The company was formerly known as Cell MedX Corp. and changed its name to StimCell Energetics Inc. in November 2024. StimCell Energetics Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.24
Low
0.30
High
52 Week Price Range
0.18
Low
0.48
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

STME (STME.US) is a Pink Sheets–listed company with limited publicly available disclosures, and its core business is not clearly documented in accessible filings. Major long-term growth drivers cannot be identified from public sources, so the equity may appeal primarily to investors seeking speculative exposure to any future operational or disclosure developments.

Primary investment risks include low trading liquidity, thin analyst coverage, potential reporting and governance deficiencies common to Pink Sheets issuers, and execution or financing uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.24
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.38
ROE
-
Net Debt
0.69M
ROCE
298.54%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-05-31 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Type yearly yearly yearly yearly yearly
Date 2026-05-31 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Income before tax -0.90M -0.57M -0.14M -0.50M -0.70M
Net income -0.90M -0.57M -0.14M -0.50M -0.70M
Selling general administrative 0.38M 0.21M 0.29M 0.36M 0.52M
Gross profit - - 0.00M 0.00M 0.00M
Reconciled depreciation - - - 0.00M 0.00M
Ebit - - -0.35M -0.45M -
Ebitda -0.82M -0.53M -0.08M -0.45M -
Depreciation and amortization - - 0.27M 0.00M -
Operating income -0.82M -0.50M -0.31M -0.45M -0.67M
Other operating expenses 0.82M 0.50M 0.31M 0.45M -
Interest expense 0.07M 0.04M 0.06M 0.05M -
Net interest income -0.07M -0.04M -0.06M -0.05M -0.03M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.01M
Total operating expenses 0.82M 0.52M 0.31M 0.45M 0.68M
Cost of revenue - - 0.00M 0.00M 0.00M
Total other income expense net -0.07M -0.06M 0.12M -0.05M -
Net income from continuing ops -0.90M -0.57M -0.14M -0.50M -0.70M
Breakdown 2026-05-31 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Type yearly yearly yearly yearly yearly
Date 2026-05-31 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Total assets 0.08M 0.02M 0.05M 0.10M 0.04M
Other current assets -0.00M 0.01M 0.00M 0.00M -
Total liab 1.89M 1.27M 0.87M 2.49M 2.05M
Total stockholder equity -1.81M -1.25M -0.83M -2.39M -2.01M
Other current liab -0.69M 0.03M 0.27M 1.08M -
Common stock 0.02M 0.02M 0.30M 0.06M -
Capital stock 0.02M 0.02M 0.02M 0.06M 0.06M
Retained earnings -11.76M -10.86M -10.30M -10.15M -9.66M
Other assets 0.08M 0.01M -0.00M -0.00M -
Cash 0.00M 0.01M 0.04M 0.10M 0.02M
Total current liabilities 0.36M 0.32M 0.87M 2.49M 2.05M
Net debt 0.69M -0.01M 0.27M 0.90M 0.59M
Short term debt 0.69M 0.46M 0.31M 1.00M -
Short long term debt 0.82M 0.46M 0.31M 1.00M 0.62M
Short long term debt total 0.69M 0.46M 0.31M 1.00M -
Other stockholder equity 9.47M 18.66M 8.74M 7.27M -
Total current assets 0.00M 0.01M 0.05M 0.10M 0.04M
Net receivables 0.00M - 0.00M 0.00M -
Inventory - - - -0.01M -
Accounts payable 0.36M 0.32M 0.29M 0.41M 0.44M
Accumulated other comprehensive income 0.45M 0.08M 0.44M 0.43M -
Non currrent assets other 0.08M - 0.00M 0.00M -
Non current assets total 0.08M 0.00M 0.00M 0.00M 0.00M
Breakdown 2026-05-31 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Type yearly yearly yearly yearly yearly
Date 2026-05-31 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Investments - - - - 0.00M
Net borrowings 0.30M 0.11M 0.02M 0.35M 0.29M
Total cash from financing activities 0.30M 0.11M 0.09M 0.35M 0.45M
Net income -0.90M -0.57M -0.14M -0.50M -0.70M
Change in cash -0.01M -0.03M -0.05M 0.07M 0.00M
Begin period cash flow 0.01M 0.04M 0.10M 0.02M 0.02M
End period cash flow 0.00M 0.01M 0.04M 0.10M 0.02M
Total cash from operating activities -0.31M -0.14M -0.15M -0.27M -0.45M
Depreciation - - - 0.00M 0.00M
Change to inventory - - - - 0.00M
Other cashflows from financing activities 0.30M 0.11M - 0.16M -
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.24M 0.26M 0.12M 0.10M 0.14M
Other non cash items 0.34M 0.42M -0.12M 0.12M 0.06M
Free cash flow -0.31M -0.14M -0.15M -0.27M -0.45M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
STME
STME
-
-%
0.24 - - 34548.53 - 103692.30 -31.71
ABT
Abbott Laboratories
-0.10
0.10%
103.87 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-
-%
100.61 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-0.13
0.04%
313.08 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
0.64
1.35%
48.14 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

STME

StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, metabolic syndrome, neuropathy, and kidney functions in the United States. It develops and manufactures the eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and the eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of the shoulder, waist, back, neck, upper and lower extremities (arms and legs). The company was formerly known as Cell MedX Corp. and changed its name to StimCell Energetics Inc. in November 2024. StimCell Energetics Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.

1130 Pender Street, West, Vancouver, BC, Canada, V6E 4A4

844 238 2692

Name Title Year Born
Mr. David M. Jeffs President, CEO & Director 1970
Ms. Yanika Silina C.M.A., C.P.A. CFO, Treasurer & Corporate Secretary 1978

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…